DeepMed Research

Ohsu Knight Cancer Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.ohsu.edu/knight-cancer-institute

Clinical Trials

Daptomycin in Treating Neutropenia and Fever in Patients With Cancer

Phase 2

Completed

Conditions: Infection
Fever
Neutropenia
Sweating
Unspecified Adult Solid Tumor, Protocol Specific
Hot Flashes

Interventions: Drug: Daptomycin

First Posted Date: 2006-06-12

Last Posted Date: 2017-05-09

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 54

Registration Number: NCT00335478

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

Interventions: Drug: Everolimus
Drug: imatinib mesylate

First Posted Date: 2006-05-31

Last Posted Date: 2017-10-26

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 23

Registration Number: NCT00331409

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

Phase 3

Terminated

Conditions: Breast Cancer
Chronic Myeloproliferative Disorders
Gestational Trophoblastic Tumor
Leukemia
Testicular Germ Cell Tumor
Infection
Multiple Myeloma and Plasma Cell Neoplasm
Lymphoma
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

Interventions: Drug: moxifloxacin hydrochloride
Drug: Placebo

First Posted Date: 2006-05-11

Last Posted Date: 2017-05-09

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 240

Registration Number: NCT00324324

Locations: 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Radiation: Intensity-Modulated Radiation Therapy (IMRT)
Drug: Docetaxel+IMRT

First Posted Date: 2006-05-04

Last Posted Date: 2024-08-29

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 25

Registration Number: NCT00321698

Locations: 🇺🇸
Veterans Affairs Medical Center - Portland, Portland, Oregon, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors

Phase 1

Completed

Conditions: Anaplastic Oligoastrocytoma
Anaplastic Oligodendroglioma
Mixed Glioma
Oligoastrocytoma

Interventions: Drug: Carboplatin
Drug: Etoposide
Drug: Etoposide Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mannitol
Drug: Melphalan
Other: Quality-of-Life Assessment
Drug: Sodium Thiosulfate

First Posted Date: 2006-03-17

Last Posted Date: 2022-03-17

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 33

Registration Number: NCT00303849

Locations: 🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Phase 1

Conditions: Central Nervous System Lymphoma

Interventions: Drug: Carboplatin
Drug: Mannitol
Drug: Methotrexate
Other: Quality-of-Life Assessment
Biological: Rituximab
Drug: Sodium Thiosulfate

First Posted Date: 2006-02-17

Last Posted Date: 2021-09-22

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 81

Registration Number: NCT00293475

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States

and more 1 locations

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Phase 2

Terminated

Conditions: Unusual Cancers of Childhood
Chronic Myeloproliferative Disorders
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Leukemia
Lymphoma

Interventions: Biological: filgrastim
Biological: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: busulfan
Drug: carmustine
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: methotrexate
Drug: cytarabine
Drug: mycophenolate mofetil
Drug: etoposide
Drug: methylprednisolone
Drug: tacrolimus
Drug: melphalan
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy
Procedure: umbilical cord blood transplantation

First Posted Date: 2006-01-25

Last Posted Date: 2017-09-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 200

Registration Number: NCT00281879

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer

Not Applicable

Terminated

Conditions: Fatigue
Unspecified Adult Solid Tumor, Protocol Specific
Anemia

Interventions: Drug: Weekly procrit dosing
Drug: Interval Dosing

First Posted Date: 2005-11-24

Last Posted Date: 2017-05-09

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 7

Registration Number: NCT00258440

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2005-11-15

Last Posted Date: 2012-06-01

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 60

Registration Number: NCT00253513

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders

Not Applicable

Terminated

Conditions: Myelodysplastic/Myeloproliferative Diseases
Lymphoma
Leukemia
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Sarcoma
Chronic Myeloproliferative Disorders
Graft Versus Host Disease

First Posted Date: 2005-11-15

Last Posted Date: 2012-05-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 4

Registration Number: NCT00253552

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy